Pfizer to pay $11.6 billion for Biohaven
By MYBRANDBOOK
Pfizer will pay $11.6 billion to buy migraine pill maker Biohaven Pharmaceutical, marking the biggest deal by the company since 2016 to beef up its portfolio ahead of patent losses for some cancer drugs.
The deal will give Pfizer access to Biohaven's approved rimegepant, a potential blockbuster that belong to a class of migraine treatments known as calcitonin gene-related peptide (CGRP) inhibitors.
Flush with about $32 billion in cash on hand after its success with COVID-19 drugs, Pfizer has been looking to add treatments as patents for its top-selling drugs like blood thinner Eliquis near expiration.
The company also expects sales of its COVID-19 vaccines to drop from last year's highs.
The Biohaven deal is its largest since Pfizer's $14 billion purchase of cancer drugmaker Medivation in 2016. Pfizer will acquire all Biohaven shares that it does not already own for $148.50 per share in cash, a 78.6 percent premium to last closing price. It had taken a 2.6 percent stake in Biohaven in November.
Biohaven shares jumped 70.1 percent to $141.39 before the bell, while Pfizer was trading flat at $48.60. With this deal, Pfizer will compete in a crowded market for migraine treatments from other large drugmakers such as Eli Lilly.
Biohaven's rimegepant, sold as Nurtec ODT in the United States, is approved for use as both a treatment and preventative for migraines and is expected to bring in sales of over $4 billion by 2030. It brought in sales of $462.5 million in 2021.
Biohaven is also developing another CGRP inhibitor and testing two non-CGRP drugs in late-stage studies.
After the deal closes, Biohaven shareholders, including Pfizer, will get 0.5 of a share of a new publicly traded company that will retain Biohaven's non-CGRP treatments.
Legal Battle Over IT Act Intensifies Amid Musk’s India Plans
The outcome of the legal dispute between X Corp and the Indian government c...
Wipro inks 10-year deal with Phoenix Group's ReAssure UK worth
The agreement, executed through Wipro and its 100% subsidiary,...
Centre announces that DPDP Rules nearing Finalisation by April
The government seeks to refine the rules for robust data protection, ensuri...
Home Ministry cracks down on PoS agents in digital arrest scam
Digital arrest scams are a growing cybercrime where victims are coerced or ...
ICONS OF INDIA : RITESH AGARWAL
Ritesh Agarwal is an Indian billionaire entrepreneur and the founder a...
Icons Of India : NANDAN NILEKANI
Nandan Nilekani is the Co-Founder and Chairman of Infosys Technologies...
ICONS OF INDIA : S KRISHNAN
S Krishnan as the secretary for the electronics and information techno...
NPCI - National Payments Corporation of India
NPCI is an umbrella organization for operating retail payments and set...
LIC - Life Insurance Corporation of India
LIC is the largest state-owned life insurance company in India...
CERT-IN - Indian Computer Emergency Response Team
CERT-In is a national nodal agency for responding to computer security...
Indian Tech Talent Excelling The Tech World - Soni Jiandani, Co-Founder- Pensando Systems
Soni Jiandani, Co-Founder of Pensando Systems, is a tech visionary ren...
Indian Tech Talent Excelling The Tech World - ARVIND KRISHNA, CEO – IBM
Arvind Krishna, an Indian-American business executive, serves as the C...
Indian Tech Talent Excelling The Tech World - JAY CHAUDHRY, CEO – Zscaler
Jay Chaudhry, an Indian-American technology entrepreneur, is the CEO a...